|
|
Volumn 32, Issue 25, 2014, Pages
|
|
Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy
a b a a b b a a a a a,c b |
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BEVACIZUMAB;
CAPECITABINE;
DASATINIB;
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
GEMCITABINE;
IXABEPILONE;
LAPATINIB;
NAVELBINE;
PACLITAXEL;
PROGESTERONE RECEPTOR;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
ERBB2 PROTEIN, HUMAN;
QUINAZOLINE DERIVATIVE;
ADULT;
AUTOPHOSPHORYLATION;
CANCER COMBINATION CHEMOTHERAPY;
CANCER DIAGNOSIS;
CANCER GROWTH;
CASE REPORT;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
COPY NUMBER VARIATION;
DRUG SUBSTITUTION;
DYSPHAGIA;
FEMALE;
FLUORESCENCE IN SITU HYBRIDIZATION;
GENE FREQUENCY;
GENE FUSION;
GENE MUTATION;
GENE SEQUENCE;
GENETIC CODE;
HUMAN;
IMMUNOHISTOCHEMISTRY;
INFLAMMATORY BREAST CANCER;
LOCAL THERAPY;
LYMPH VESSEL METASTASIS;
MIDDLE AGED;
NOTE;
PHYSICAL EXAMINATION;
PRIORITY JOURNAL;
SKIN BIOPSY;
TREATMENT OUTCOME;
TUMOR RECURRENCE;
CARCINOMA, DUCTAL, BREAST;
ENZYMOLOGY;
GENETICS;
INFLAMMATORY BREAST NEOPLASMS;
METABOLISM;
MOLECULARLY TARGETED THERAPY;
PATHOLOGY;
TRIPLE NEGATIVE BREAST NEOPLASMS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CARCINOMA, DUCTAL, BREAST;
FEMALE;
HUMANS;
INFLAMMATORY BREAST NEOPLASMS;
MIDDLE AGED;
MOLECULAR TARGETED THERAPY;
QUINAZOLINES;
RECEPTOR, ERBB-2;
TRIPLE NEGATIVE BREAST NEOPLASMS;
|
|
EID: 84905469625
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2013.49.0599 Document Type: Note |
|
Times cited : (43)
|
|
References (9)
|
